Disorders of the Acute Phase Response Following Trauma and Invasive Surgery
Launched by VANDERBILT UNIVERSITY MEDICAL CENTER · Nov 12, 2018
Trial Information
Current as of July 01, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Significance: Severe injury is a leading cause of death and disability worldwide, affecting approximately 2.8 million individuals and accounting for over 200,000 deaths annually across the United States1,2,3. Large cohort studies have demonstrated that approximately 64% of trauma-related deaths are due to complications including thrombosis, bleeding, infection, and organ dysfunction, and each complication corresponds with an 8% increase in risk of mortality4. While advances in critical care medicine have significantly improved the initial survival from traumatic injuries, the proportion of ...
Gender
ALL
Eligibility criteria
- • Arm 1: Level I Trauma Patients Inclusion criteria
- • Any patient admitted to or treated in the VUMC Adult Trauma Unit
- • Patients ages 16 and older (all included in the adult trauma unit admissions)
- • Patients will be divided into sub-groups for analyses based on type of trauma (TBI, blunt force trauma, polytrauma, etc) and severity (Level 1 vs non-level 1 trauma)
- • Exclusion criteria
- • • None
- • Arm 2: Invasive Elective Surgical Patients Inclusion criteria
- • Any patient admitted for an invasive elective surgery associated with high blood loss or a high risk of vascular complications at VUMC/VCH. Enrollment will be at the discretion of the attending physician
- • This may include, but is not limited to, orthopedic and vascular surgery patients
- • Patients ages 2 months and older Exclusion criteria
- • None
- • Arm 3: Healthy Volunteers Inclusion criteria
- • Volunteers should be male or female
- • Age 18-70 years of age
- • Weight greater than 110lbs
- • Exclusion criteria
- • Chronic medical conditions such as: diabetes, hypertension, high cholesterol, rheumatologic disorders, infections, etc.
- • No history of recent traumatic injury (within the past year)
- • Pregnant females or people on hormone replacement therapy
- • People on any anticoagulant medication or NSAIDS
About Vanderbilt University Medical Center
Vanderbilt University Medical Center (VUMC) is a leading academic medical center located in Nashville, Tennessee, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, VUMC integrates cutting-edge scientific inquiry with patient-centered care, supporting a diverse array of studies aimed at enhancing medical knowledge and improving treatment outcomes. With a robust infrastructure and a multidisciplinary team of experts, VUMC fosters collaboration across various fields, ensuring the highest standards of safety and ethical considerations in its research endeavors. Through its dedication to medical discovery and education, VUMC plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nashville, Tennessee, United States
Patients applied
Trial Officials
Jonathan Schoenecker, MD, PhD
Principal Investigator
Vanderbilt University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials